Lectin-Fusion for Bone/Muscle Disorders
Musculoskeletal pathologies, abnormal bone growth
Pre-clinicalActive
Key Facts
Indication
Musculoskeletal pathologies, abnormal bone growth
Phase
Pre-clinical
Status
Active
Company
About SylamoreBio
SylamoreBio is a private, pre-clinical stage biotech leveraging a proprietary RTB-lectin-based delivery platform to target CNS and other challenging tissues. The technology uses a sugar-binding lectin for receptor-independent cellular uptake, potentially enabling effective delivery of enzymes, antibodies, and RNAs across the blood-brain barrier and into avascular tissues like bone. The company is addressing a critical unmet need in lysosomal storage disorders and other conditions where current therapies are hindered by delivery challenges and anti-drug antibodies.
View full company profile